Dashboard
Manage Tickers

ALXOALX ONCOLOGY HOLDINGS INC

Nasdaq alxoncology.com


$ 2.50 $ -0.03 (-1.19 %)    

Wednesday, 21-Aug-2024 12:48:48 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 481.33 $ 0.21 (0.04 %)
DIA $ 408.64 $ -0.60 (-0.15 %)
SPY $ 559.91 $ -0.02 (-0 %)
TLT $ 98.78 $ 0.10 (0.1 %)
GLD $ 231.78 $ 0.12 (0.05 %)
$ 2.51
$ 2.53
$ 2.50 x 100
$ 2.51 x 200
$ 2.47 - $ 2.54
$ 2.42 - $ 17.83
874,900
na
130.1M
$ 1.61
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2024 06-30-2024 10-Q
2 05-09-2024 03-31-2024 10-Q
3 03-07-2024 12-31-2023 10-K
4 11-13-2023 09-30-2023 10-Q
5 08-10-2023 06-30-2023 10-Q
6 05-11-2023 03-31-2023 10-Q
7 03-09-2023 12-31-2022 10-K
8 11-08-2022 09-30-2022 10-Q
9 08-08-2022 06-30-2022 10-Q
10 05-09-2022 03-31-2022 10-Q
11 02-28-2022 12-31-2021 10-K
12 11-12-2021 09-30-2021 10-Q
13 08-12-2021 06-30-2021 10-Q
14 05-17-2021 03-31-2021 10-Q
15 03-18-2021 12-31-2020 10-K
16 11-12-2020 09-30-2020 10-Q
17 08-27-2020 06-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

ubs-maintains-buy-on-alx-oncology-holdings-lowers-price-target-to-4
UBS Maintains Buy on ALX Oncology Holdings...
08/16/2024 14:28:37

UBS analyst Colin Bristow maintains ALX Oncology Holdings (NASDAQ:ALXO) with a Buy and lowers the price target from $25 to $4.

hc-wainwright--co-reiterates-buy-on-alx-oncology-holdings-maintains-25-price-target
HC Wainwright & Co. Reiterates Buy on ALX ...
08/13/2024 11:19:33

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates ALX Oncology Holdings (NASDAQ:ALXO) with a Buy and maintai...

cantor-fitzgerald-reiterates-overweight-on-alx-oncology-holdings
Cantor Fitzgerald Reiterates Overweight on...
08/12/2024 12:35:56

Cantor Fitzgerald analyst Li Watsek reiterates ALX Oncology Holdings (NASDAQ:ALXO) with a Overweight.

stifel-reiterates-hold-on-alx-oncology-holdings-lowers-price-target-to-3
Stifel Reiterates Hold on ALX Oncology Hol...
08/09/2024 12:25:14

Stifel analyst Bradley Canino reiterates ALX Oncology Holdings (NASDAQ:ALXO) with a Hold and lowers the price target from $5...

alx-oncology-holdings-q2-eps-076-beats-077-estimate
ALX Oncology Holdings Q2 EPS $(0.76) Beats...
08/08/2024 21:28:12

ALX Oncology Holdings (NASDAQ:ALXO) reported quarterly losses of $(0.76) per share which beat the analyst consensus estimate of...

crude-oil-moves-lower-moderna-shares-plunge
Crude Oil Moves Lower; Moderna Shares Plunge
08/01/2024 18:34:37

dow-dips-over-500-points-ism-manufacturing-pmi-falls-in-july
Dow Dips Over 500 Points; ISM Manufacturin...
08/01/2024 16:06:46

stifel-maintains-hold-on-alx-oncology-holdings-lowers-price-target-to-5
Stifel Maintains Hold on ALX Oncology Hold...
08/01/2024 14:22:06

Stifel analyst Bradley Canino maintains ALX Oncology Holdings (NASDAQ:ALXO) with a Hold and lowers the price target from $14...

nasdaq-surges-1-meta-posts-upbeat-earnings
Nasdaq Surges 1%; Meta Posts Upbeat Earnings
08/01/2024 14:15:23

immuno-oncology-focused-alx-oncology-stock-falls-on-updated-data-from-mid-stage-evorpacept-combo-study-in-gastric-cancer-patients
Immuno-Oncology Focused ALX Oncology Stock...
08/01/2024 13:05:15

ALX Oncology announces Phase 2 ASPEN-06 trial results for evorpacept in combination with trastuzumab, Cyramza, and paclitaxel f...

hc-wainwright--co-reiterates-buy-on-alx-oncology-holdings-maintains-25-price-target
HC Wainwright & Co. Reiterates Buy on ALX ...
08/01/2024 13:01:43

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates ALX Oncology Holdings (NASDAQ:ALXO) with a Buy and maintai...

why-carvana-shares-are-trading-higher-by-13-here-are-20-stocks-moving-premarket
Why Carvana Shares Are Trading Higher By 1...
08/01/2024 12:32:25

Core News & Articles
Market-Moving News for August 1st
08/01/2024 12:21:36

META: 8% | Meta shares are trading higher after the company reported better-than-expected Q2 financial results and issued Q3 gu...

trading-halt-halt-status-updated-at-42500-pm-et-quotation-resumption-news-and-resumption-times
Trading Halt: Halt status updated at 4:25:...
07/31/2024 20:25:07

alx-oncology-reports-data-from-aspen-06-phase-2-trial-says-evorpacept-combination-achieved-confirmed-overall-response-rate-of-403-compared-to-266-for-control-arm
ALX Oncology Reports Data From ASPEN-06 Ph...
07/31/2024 20:03:56

Evorpacept is the first CD47 blocker to show durable clinical benefit and a well-tolerated safety profile in a prospective rand...

trading-halt-halted-at-40010-pm-et---trading-halt-halt-news-pending
Trading Halt: Halted at 4:00:10 p.m. ET - ...
07/31/2024 20:00:17

alx-oncology-to-announce-phase-2-trial-results-for-her2-positive-gastric-cancer-at-430-pm-edt
ALX Oncology to Announce Phase 2 Trial Res...
07/31/2024 09:34:59

ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:ALXO), an immuno-oncology company develop...

hc-wainwright--co-reiterates-buy-on-alx-oncology-holdings-maintains-25-price-target
HC Wainwright & Co. Reiterates Buy on ALX ...
06/10/2024 10:57:58

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates ALX Oncology Holdings (NASDAQ:ALXO) with a Buy and maintai...

alx-oncology-reported-phase-1-aspen-07-data-in--in-patients-with-advanced-bladder-cancer-at-asco-2024-initial-activity-showed-tumor-reduction-in-the-majority-of-evaluable-patients
ALX Oncology Reported Phase 1 ASPEN-07 Dat...
06/02/2024 14:13:51

ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (NASDAQ: ALXO), an immuno-oncology company developing therapies t...

cantor-fitzgerald-reiterates-overweight-on-alx-oncology-holdings
Cantor Fitzgerald Reiterates Overweight on...
05/29/2024 13:15:00

Cantor Fitzgerald analyst Li Watsek reiterates ALX Oncology Holdings (NASDAQ:ALXO) with a Overweight.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION